CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

125388Orig1s000

OFFICE DIRECTOR MEMO
Office Director Decisional Memo

Date: August 19, 2011
From: Richard Pazdur, MD
Subject: Office Director Decisional Memo
NDA/BLA #: 125388
Supplement #: 
Applicant Name: Seattle Genetics, Inc.
Date of Submission: February 28, 2011
PDUFA Goal Date: August 30, 2011
Proprietary Name / Established (USAN) Name: Adcetris/brentuximab vedotin
Dosage Forms / Strength: Intravenous infusion administered at 1.8 mg/kg every 21 days/ 50 mg single use vial
Proposed Indication(s): Treatment of Relapsed or Refractory Hodgkin Lymphoma
Action/Recommended Action for NME: Accelerated Approval

Material Reviewed/Consulted
OND Action Package, including:
Medical Officer Review: Angelo De Claro, M.D./ Virginia Kwitkowski, RNP
Statistical Review: Kyung Yul Lee, Ph.D./Mark Rothmann, Ph.D.
Pharmacology Toxicology Review: Yanli Ouyang Ph.D./ Haled Saber, Ph.D.
CMC Review/OBP and ONDQA Reviews and Micro review: Bo Chi Ph.D./Colleen Thomas, Ph.D./Patricia Hughes, Ph.D./Francisco Borrego, Ph.D./ Marjorie Shapiro, Ph.D./Patrick Swann, Ph.D./Kathleen Clouse, Ph.D./ Xiao Hong Chen, Ph.D./Janice Brown, Ph.D./Sarah Pope-Miksinski, Ph.D./Richard Lustritto, Ph.D.
Microbiology Review: See list above.
Clinical Pharmacology Review: A. Khandelwal, Ph.D./ Julie Bullock, Pharm.D.
DDMAC: Adam George, R.Ph.
DSI: Lauren Iacono-Connors, Ph.D./Jean Mulinde, M.D.
CDTL Review: Virginia Kwitkowski, RNP
OSE/DMEPA: Walter Fava, R. Ph., MEd./ Carlos Mena-Grillasca, R. Ph./ Carol Holquist, R. Ph.
OSE/DDRE: 
OSE/DSRCS: 
Other –MHT IRT: 1. Tammie Brent-Howard RN, MSN/Karen Feibus, M.D.
2. Jeannie Best MSN, RN, PNP/ Hari Sachs, M.D.
IRT review team/Norman Stockbridge, M.D.
1. Introduction

On February 28, 2011, Seattle Genetics submitted BLA 125388 proposed for the treatment of patients with relapsed or refractory Hodgkin Lymphoma (HL). On the same date, the sponsor submitted BLA 125399 for systemic anaplastic large cell lymphoma (ALCL); however, there is a separate decisional memo for that application.

Brentuximab vedotin is a drug-antibody conjugate [(cAC10) conjugated to SGD-1006 via thioether bonds] directed against CD30. Brentuximab vedotin has 3 components: a chimeric IgG1 antibody cAC10 specific for human CD30, an antimitotubule agent monomethyl auristatin E (MMAE), and a protease-cleavable linker that is covalently attached MMAE to cAC10. Binding of the ADC to CD30 on the cell surface initiates internalization of the ADC-CD30 complex. Within the cell, MMAE is released via proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, induces cell cycle arrest, and results in apoptotic death of the CD30-expressing tumor cell.

Hodgkin lymphoma is a hematologic malignancy characterized by the presence of Reed-Sternberg cells. Symptoms include painless enlargement of lymph nodes, spleen or other immune tissue. Other symptoms include fever, weight loss, fatigue, and night sweats.

The majority of patients who receive adequate first-line therapy (radiation or chemotherapy or a combination) are cured of their disease. However those patients with Hodgkin lymphoma who relapse or do not respond to first-line therapy will require additional therapy consisting of high-dose chemotherapy and autologous stem cell transplant (ASCT). Up to 40% of patients receiving autologous stem cell transplant eventually relapse with a historical median survival is 2 years from time of relapse post-ASCT.

2. CMC/Device

The CMC and Product review teams recommend that this application be approved.

Product quality recommends an expiration dating period of 30 months for brentuximab vedotin drug product when stored at 2-8°C, an expiration dating period of [9] for brentuximab vedotin drug substance when stored at [9], and an expiration dating period of [9] for cAC10 Intermediate when stored at [9]. Also, the stability protocols were acceptable and product quality recommends approval of the proposed release specifications for brentuximab vedotin drug product, brentuximab vedotin drug substance and cAC10 Intermediate.

There are no issues identified that preclude approval; however, there are several post-marketing commitments (PMCs) for product quality. Please refer to the action letter for these PMCs.

3. Nonclinical Pharmacology/Toxicology

There are no pharmacology/toxicology issues at this time that will preclude the approval of brentuximab vedotin for the proposed indications. Pharmacology and toxicology studies with brentuximab vedotin and/or MMAE were conducted according to ICHS9 and are considered adequate.
4. Clinical Pharmacology/Biopharmaceutics

The Clinical Pharmacology and Biopharmaceutics team recommended approval, and there are no issues that would preclude approval.

5. Microbiology

The Microbiology team has not identified issues that would preclude approval of the BLA.

6. Clinical/Statistical-Efficacy

The main trial to support accelerated approval of this application is SG0-35-003, which is a Phase 2, single arm clinical trial where brentuximab vedotin showed a 32% complete remission rate with a median duration of response of 20.5 months. This trial is supported by phase 1 data and a second phase 2 single arm study, SG035-004, in a related disease ALCCL.

SG035-0003 enrolled 102 patients with Hodgkin lymphoma who relapsed after autologous stem cell transplant. The historical median overall survival for these patients is approximately 2 years from time of relapse post-transplant.

The trial population was mostly young adults, and the mean age was 34 years. Seventy-five percent of the patients were between the ages of 18 to 39. The median number of prior lines of systemic chemotherapy was 5. Nearly all of the patients had received drugs or drug classes approved for the treatment of Hodgkin lymphoma.

The primary efficacy endpoint in the Hodgkin lymphoma trial, ORR by Independent Review Facility, was 73% (95% CI: 65, 83) with a median duration of 6.7 months (95% CI: 4, 14.8). Complete Remission (CR) rate was 32% (95% CI: 23.3, 42.3) with a median duration of 20.5 months (95% CI: 12, NE). Partial Remission (PR) rate was 40% (95% CI: 31.5, 49.4) with a median duration of 3.5 months (95% CI: 2.2, 4.1).

7. Safety

Safety information for the HL and ALCCL trials were reviewed and incorporated into labeling.

The most common adverse reactions (≥20%) noted in both trials were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough and vomiting. Serious adverse events (SAEs) were reported in 31% of patients. The most common (>2%) SAEs reported were peripheral motor neuropathy, urinary tract infection, and abdominal pain. Refer to the prescribing information link below for further details of safety profiles of the individual trials.

Of note, a high percentage of patients reported to have unresolved residual neuropathy, therefore, further follow-up of this adverse event is recommended to determine whether the neuropathy is permanent or resolves very gradually.
8. Advisory Committee Meeting

On July 14, 2011, the Oncologic Drugs Advisory Committee (ODAC) met in the morning to discuss this application. ODAC voted unanimously in favor of accelerated approval for this application.

9. Pediatrics

Brentuximab is exempt from the requirement for pediatric studies for the HL indication because of orphan drug designation.

10. Other Relevant Regulatory Issues

There are no outstanding regulatory issues that would preclude approval of this application.

11. Labeling

All disciplines made recommendations for labeling which were incorporated.

12. Decision/Action/Risk Benefit Assessment

- Recommended regulatory action
  Accelerated Approval

- Risk Benefit Assessment
  The risk benefit assessment favors approval of brentuximab vedotin for the treatment of patients with Hodgkin Lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for an autologous stem cell transplant. The overall response rate was impressive. The responses were durable for those who achieved a complete remission (median: 20.5 months duration for CRs). The responses were not very durable for those whose disease achieved a partial response (median 3.5 months for PRs). The safety database was limited as only 102 patients were enrolled in SG035-0003. The major adverse events were neuropathy, neutropenia, and infusion reactions.

  The Division had recommended an accelerated approval requiring randomized studies to be performed to better characterize the risk to benefit analysis. This was discussed at ODAC with a unanimous vote to support accelerated approval rather than regular approval. This data that will covert this accelerated approval to regular approval will come from randomized studies combining brentuximab to chemotherapy regimens in less refractory disease settings in both Hodgkin lymphoma and anaplastic large cell lymphoma. In addition, the submission of safety data from a randomized trial comparing brentuximab to placebo in a maintenance trial in Hodgkin lymphoma can also provide supporting information.

  The benefits and risks of brentuximab were discussed in the Division Director’s Summary Review, the CDTL and Clinical Reviews. The review team found the risk-benefit assessment to be acceptable for the recommended regulatory action of accelerated approval (see above).
conclusion, I concur with the review team’s recommendation as well as the unanimous vote of the ODAC supporting accelerated approval.

- Recommendation for Post marketing Risk Management Activities
  Routine Surveillance

- Recommendation for other Post marketing Study Requirements/ Commitments:

See action letter for PMRs and PMCs. Since this BLA is being approved under Accelerated Approval, the sponsor is required to conduct a confirmatory trial to be considered for full approval.